Compare Analog Devices, Inc. (ADI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Analog Devices, Inc. trades at $386.26 (market cap $187.00B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Analog Devices, Inc. is the larger of the two by market cap, and Analog Devices, Inc. pays a 1.15% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ADI | VRTX | |
|---|---|---|
Market Cap | $187.00B | $132.79B |
Sector | Technology | Health |
52-Week High | $445.48 | $529.65 |
52-Week Low | $225.20 | $376.62 |
Enterprise Value | $192.25B | $126.92B |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $389.93, up 3.34% over the past day, with a bullish technical signal and strong institutional support. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.09 exceeding expectations. Revenue for 2025 reached $11.02 billion, with a net income margin of 26.01%, though valuation ratios like P/E of 58.03 suggest premium pricing. A dividend of $1.10 per share is scheduled for payment on June 16, 2026.
The outlook for ADI is positive, driven by robust earnings performance and analyst optimism, with a consensus price target of $474.80 implying significant upside. Risks include high valuation multiples and sensitivity to semiconductor market cycles, but strong cash flow and institutional buy-in support a favorable investment case for growth-oriented investors.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
